Moreover from the point of view of Merck, if they have Keytruda (which has a patent till 2028) they want a new formulation, which can extend the runway, rather than something to add to the existing Keytruda formualtion. V attractive will buy something to extend out their runway.
Ann: Imugene HER-Vaxx Clinical Trial Collaboration with Merck, page-52
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.001(2.04%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $424.8K | 8.751M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 69 | 8622849 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 1925890 | 9 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |